Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

2019: An Awesome Year for Pharmaceuticals.

Vanden Eynde JJ.

Pharmaceuticals (Basel). 2020 Jan 1;13(1). pii: E6. doi: 10.3390/ph13010006.

2.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6.

Vanden Eynde JJ, Mangoni AA, Rautio J, Leprince J, Azuma YT, García-Sosa AT, Hulme C, Jampilek J, Karaman R, Li W, Gomes PAC, Hadjipavlou-Litina D, Capasso R, Geronikaki A, Cerchia L, Sabatier JM, Ragno R, Tuccinardi T, Trabocchi A, Winum JY, Luque FJ, Prokai-Tatrai K, Spetea M, Gütschow M, Kosalec I, Guillou C, Vasconcelos MH, Kokotos G, Rastelli G, de Sousa ME, Manera C, Gemma S, Mangani S, Siciliano C, Galdiero S, Liu H, Scott PJH, de Los Ríos C, Agrofoglio LA, Collina S, Guedes RC, Muñoz-Torrero D.

Molecules. 2019 Dec 28;25(1). pii: E119. doi: 10.3390/molecules25010119.

3.

Bioactive Aliphatic Polycarbonates Carrying Guanidinium Functions: An Innovative Approach for Myotonic Dystrophy Type 1 Therapy.

Baroni A, Neaga I, Delbosc N, Wells M, Verdy L, Ansseau E, Vanden Eynde JJ, Belayew A, Bodoki E, Oprean R, Hambye S, Blankert B.

ACS Omega. 2019 Oct 21;4(19):18126-18135. doi: 10.1021/acsomega.9b02034. eCollection 2019 Nov 5.

4.

Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric Analogues.

Toulouse JL, Yachnin BJ, Ruediger EH, Deon D, Gagnon M, Saint-Jacques K, Ebert MCCJC, Forge D, Bastien D, Colin DY, Vanden Eynde JJ, Marinier A, Berghuis AM, Pelletier JN.

ACS Omega. 2019 Jun 10;4(6):10056-10069. doi: 10.1021/acsomega.9b00640. eCollection 2019 Jun 30.

5.

Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria.

Mayence A, Vanden Eynde JJ.

Pharmaceuticals (Basel). 2019 Jul 30;12(3). pii: E115. doi: 10.3390/ph12030115.

6.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5.

Mangoni AA, Eynde JJV, Jampilek J, Hadjipavlou-Litina D, Liu H, Reynisson J, Sousa ME, Gomes PAC, Prokai-Tatrai K, Tuccinardi T, Sabatier JM, Luque FJ, Rautio J, Karaman R, Vasconcelos MH, Gemma S, Galdiero S, Hulme C, Collina S, Gütschow M, Kokotos G, Siciliano C, Capasso R, Agrofoglio LA, Ragno R, Muñoz-Torrero D.

Molecules. 2019 Jun 30;24(13). pii: E2415. doi: 10.3390/molecules24132415.

7.

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases.

Mayence A, Vanden Eynde JJ.

Pharmaceuticals (Basel). 2019 Mar 12;12(1). pii: E37. doi: 10.3390/ph12010037.

8.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes⁻4.

Mangoni AA, Guillou C, Vanden Eynde JJ, Hulme C, Jampilek J, Li W, Prokai-Tatrai K, Rautio J, Collina S, Tuccinardi T, Sousa ME, Sabatier JM, Galdiero S, Karaman R, Kokotos G, Torri G, Luque FJ, Vasconcelos MH, Hadjipavlou-Litina D, Siciliano C, Gütschow M, Ragno R, Gomes PAC, Agrofoglio LA, Muñoz-Torrero D.

Molecules. 2018 Dec 31;24(1). pii: E130. doi: 10.3390/molecules24010130.

9.

Correction to: Affinity capillary electrophoresis for identification of active drug candidates in myotonic dystrophy type 1.

Neaga IO, Hambye S, Bodoki E, Palmieri C, Vanden Eynde JJ, Ansseau E, Belayew A, Oprean R, Blankert B.

Anal Bioanal Chem. 2019 Jan;411(2):545. doi: 10.1007/s00216-018-1460-5.

PMID:
30443771
10.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3.

Mangoni AA, Tuccinardi T, Collina S, Vanden Eynde JJ, Muñoz-Torrero D, Karaman R, Siciliano C, de Sousa ME, Prokai-Tatrai K, Rautio J, Guillou C, Gütschow M, Galdiero S, Liu H, Agrofoglio LA, Sabatier JM, Hulme C, Kokotos G, You Q, Gomes PAC.

Molecules. 2018 Jun 30;23(7). pii: E1596. doi: 10.3390/molecules23071596. No abstract available.

11.

Third International Electronic Conference on Medicinal Chemistry (ECMC-3).

Mayence A, Eynde JJV.

Pharmaceuticals (Basel). 2018 Feb 9;11(1). pii: E18. doi: 10.3390/ph11010018.

12.

2017: A Fruitful Year for Pharmaceuticals.

Vanden Eynde JJ.

Pharmaceuticals (Basel). 2017 Dec 21;11(1). pii: E1. doi: 10.3390/ph11010001.

13.

Pharmaceuticals: Impact Factor or CiteScore™.

Vanden Eynde JJ.

Pharmaceuticals (Basel). 2017 Jul 6;10(3). pii: E61. doi: 10.3390/ph10030061.

14.

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Vanden Eynde JJ.

Pharmaceuticals (Basel). 2017 May 22;10(2). pii: E48. doi: 10.3390/ph10020048.

15.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes.

Muñoz-Torrero D, Mangoni AA, Guillou C, Collina S, Vanden Eynde JJ, Rautio J, Keserű GM, Hulme C, Chibale K, Luque FJ, Karaman R, Gütschow M, Liu H, Ragno R.

Molecules. 2017 May 5;22(5). pii: E743. doi: 10.3390/molecules22050743.

16.

Potential of bisbenzimidazole-analogs toward metronidazole-resistant Trichomonas vaginalis isolates.

Korosh T, Bujans E, Morada M, Karaalioglu C, Vanden Eynde JJ, Mayence A, Huang TL, Yarlett N.

Chem Biol Drug Des. 2017 Oct;90(4):489-495. doi: 10.1111/cbdd.12972. Epub 2017 Apr 25.

PMID:
28296056
17.

Second International Electronic Conference on Medicinal Chemistry (ECMC-2).

Mayence A, Eynde JJ.

Pharmaceuticals (Basel). 2017 Jan 31;10(1). pii: E20. doi: 10.3390/ph10010020.

18.

Progress Confirmed for Pharmaceuticals in 2016.

Vanden Eynde JJ.

Pharmaceuticals (Basel). 2016 Dec 26;10(1). pii: E1. doi: 10.3390/ph10010001.

19.

Announcing the 2016 Pharmaceuticals Travel Award for Young Investigators.

Vanden Eynde JJ.

Pharmaceuticals (Basel). 2016 Jun 27;9(3). pii: E35. doi: 10.3390/ph9030035.

20.

Evaluation of bisbenzamidines as inhibitors for matriptase-2.

Beckmann AM, Gilberg E, Gattner S, Huang TL, Vanden Eynde JJ, Mayence A, Bajorath J, Stirnberg M, Gütschow M.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3741-5. doi: 10.1016/j.bmcl.2016.05.071. Epub 2016 May 26.

PMID:
27287367

Supplemental Content

Loading ...
Support Center